Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
OncoZenge Logo
OncoZenge Growth Score
60
CB Rank
42301
Heat Score
65
OncoZenge develops better products for the supportive care of cancer patients.
Founded
obfuscation
PublicPost-IPO Equity Bromma, Sodermanlands Lan, Sweden1-10 oncozenge.se/
Biotechnology
Health Care
Pharmaceutical
Overview

OncoZenge
Total Funding
obfuscation
Growth Score
60
Heat Score
65

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score60
-5 pts
in past quarter
Heat Score 65
34 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About OncoZenge

CB Rank
42301
OncoZenge develops better products for the supportive care of cancer patients.
Founded
obfuscation
PublicPost-IPO Equity Bromma, Sodermanlands Lan, Sweden1-10 oncozenge.se/
Biotechnology
Health Care
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Details

Legal Name OncoZenge AB
Operating Status Active
Stock Symbol  NASDAQ:ONCOZ
Company Type For Profit
About the Company
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer patients.
Contact Email info@oncozenge.se
Predictions & Insights

Growth Insight

See this Growth Insight
OncoZenge is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction

Products & Services

BupiZenge™
An oral lozenge formulation of bupivacaine designed to relieve oral pain caused by oral mucositis in cancer patients undergoing radiotherapy or chemotherapy.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - OncoZenge Logo
Post-IPO Equity - OncoZenge
1
obfuscation
Sichuan Yangtian Bio-PharmaceuticalPost-IPO Equity
obfuscation
Post-IPO Equity - OncoZenge Logo
Post-IPO Equity - OncoZenge
1
obfuscation
Sichuan Yangtian Bio-PharmaceuticalPost-IPO Equity
obfuscation
Post-IPO Equity - OncoZenge Logo
Post-IPO Equity - OncoZenge
1
obfuscation
Sichuan Yangtian Bio-PharmaceuticalPost-IPO Equity
obfuscation
Post-IPO Equity - OncoZenge Logo
Post-IPO Equity - OncoZenge
1
obfuscation
Sichuan Yangtian Bio-PharmaceuticalPost-IPO Equity
obfuscation
Post-IPO Equity - OncoZenge Logo
Post-IPO Equity - OncoZenge
1
obfuscation
Sichuan Yangtian Bio-PharmaceuticalPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 4
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - OncoZenge Logo
Post-IPO Equity - OncoZenge
1
obfuscation
Sichuan Yangtian Bio-PharmaceuticalPost-IPO Equity
obfuscation
Post-IPO Equity - OncoZenge Logo
Post-IPO Equity - OncoZenge
1
obfuscation
Sichuan Yangtian Bio-PharmaceuticalPost-IPO Equity
obfuscation
Post-IPO Equity - OncoZenge Logo
Post-IPO Equity - OncoZenge
1
obfuscation
Sichuan Yangtian Bio-PharmaceuticalPost-IPO Equity
obfuscation
Post-IPO Equity - OncoZenge Logo
Post-IPO Equity - OncoZenge
1
obfuscation
Sichuan Yangtian Bio-PharmaceuticalPost-IPO Equity
obfuscation
Post-IPO Equity - OncoZenge Logo
Post-IPO Equity - OncoZenge
1
obfuscation
Sichuan Yangtian Bio-PharmaceuticalPost-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Contacts 1
News

News and Press

News•Jun 5, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

IT Spend

$6.5KThis year, OncoZenge is projected to spend $6.5K on IT, according to Aberdeen.

Active Website Tech Count

1OncoZenge is actively using the technology Pound Sterling for its website, according to BuiltWith.

Total IP

8The intellectual property of OncoZenge includes 3 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, OncoZenge has registered 5 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is OncoZenge's headquarters? OncoZenge is located in Bromma, Sodermanlands Lan, Sweden.Who invested in OncoZenge? OncoZenge has 3 investors including Sichuan Yangtian Bio-Pharmaceutical and  Linc.When was the last funding round for OncoZenge? OncoZenge closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are OncoZenge's competitors? Alternatives and possible competitors to OncoZenge may include InterMed Pharmaceutical Laboratories, Schaer Pharma, and  Sager Dental.How much funding has OncoZenge raised to date? OncoZenge has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(411cf44 1)
|